Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28579522 | 0.89 | SMO (0.59) | SMOALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL5336139 | 0.89 | SMO (0.47) | SMOPOLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6967030 | 0.89 | KCNK3 (0.55) | SMOPOLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28574727 | 0.85 | NPC1 (0.51) | SMOPOLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6344638 | 0.85 | MAPK1 (0.51) | SMOPOLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1437533 | 0.84 | FADS1 (0.53) | ALDH1A1RAB9AKMT2ANPC1MEN1 | |
| SCHEMBL28567907 | 0.82 | NPC1 (0.51) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL28914211 | 0.81 | KCNK3 (0.57) | POLBALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL28573597 | 0.81 | RAB9A (0.49) | SMOPOLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28913723 | 0.81 | RAB9A (0.48) | SMOALDH1A1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108084110-B | 3-aminobenzo [ d ] isothiazole, derivative and synthetic method thereof | 湘潭大学 | 2021-05-07 | — | — | CN | disclosed |
| US-20010051630-A1 | Use of hydroxylamine derivatives, and method and preparations for increasing the tolerance of field crops against weather stresses | JEDNAKOVITS ANDREA (HU) | 2001-12-13 | — | — | US | disclosed |
| EP-1018876-A1 | USE OF HYDROXYLAMINE DERIVATIVES, AND METHOD AND PREPARATIONS FOR INCREASING THE TOLERANCE OF FIELD CROPS AGAINST WEATHER STRESSES | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998047362-A1 | USE OF HYDROXYLAMINE DERIVATIVES, AND METHOD AND PREPARATIONS FOR INCREASING THE TOLERANCE OF FIELD CROPS AGAINST WEATHER STRESSES | Biorex Kutató és Fejlesztó Rt. (HU) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051630-A1 | Use of hydroxylamine derivatives, and method and preparations for increasing the tolerance of field crops against weather stresses | CYP8B1, HDHD5, AHSA1 | SMO 4791/4885POLB 3244/4885ALDH1A1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.